26 July 2017
Blueberry to progress Nanomedicine platform to include novel Acne therapy
Blueberry Therapeutics Ltd is pleased to announce that it has taken a significant step forward in the development of new Acne treatments by gaining support from Innovate UK to co-fund critical research of this exciting programme. Principal Scientist Christine Ridden said “Thanks to the support from Innovate UK we will be able to rapidly asses the feasibility of a range of new topical nanomedicnes for the treatment of acne. If successful, these new medicines will represent a step forward in acne treatment with dual action therapies that tackle the symptoms of acne whilst preventing disease progression”. This is another important step in building our pipeline and follows the entry of our lead product, BB2603 for Onychomycosis, into clinical trials earlier this year.
Blueberry Therapeutics Ltd. is a modern drug discovery and development company which is focused on treating infectious dermatological disorders in the short term, and addressing the global problem of antibiotic resistance in the long term. Blueberry employs state of the art technologies including nanotechnology based topical delivery systems and biologic and small molecule lead platforms to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability, we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic.